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INTRODUCTION
The behaviour of differentiated thyroid cancers in
endemic areas is reportedly different from that in non-
endemic areas. In endemic areas, not only is there a
preponderance of follicular and anaplastic cancers, both
recognized for their virulent nature, even papillary cancers
reportedly have more aggressive behaviour.1,2 We
conducted a retrospective study of 289 thyroid cancer
cases from an area endemic for goitres in an effort to
identify the various prognostic factors for differentiated
thyroid cancers.
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A retrospective analysis of 215 differentiated thyroid cancers was undertaken to identify the various
prognostic variables. There were 132 papillary and 83 follicular cancers; both histologic types occurred
at an earlier age, with a male to female ratio of 1: 1.1 (signifies near parity in both sexes, in contrast
to marked female preponderance in most of the reports and amongst benign thyroid disorders). There
was a significant difference in the size of the primary tumours; 60/132 (45%) of papillary and 30/83
(36%) of follicular cancers were early T0-1 lesions and 20 (15%) papillary and 24 (29%) follicular
cancers were advanced T3 lesions. Age did not affect the size of the primary tumour. Regional lymph
node and pulmonary metastases were common in both types of cancer while distant metastases
occurred more frequently in follicular cancers (p < 0.005). Following surgery, contralateral lobe
recurrence in the remaining lobe was more common in the follicular cancer group, while loco-regional
recurrence after near-total thyroidectomy was more frequent in the papillary cancer group (p > 0.05).
Mortality in 26/132 (20%) papillary and 28/83 (34%) follicular cancer patients was high in both
groups, but significantly higher in the follicular cancer group (p < 0.05). Although mortality among
patients with papillary cancer was higher in patients older than 40 years of age (p < 0.05), age did not
affect survival in patients with follicular cancer. Gender did not affect survival in either group. The
extent of the disease at presentation was the most important determinant of survival, with mortality
significantly higher among patients with T3N3M1 lesions (p < 0.001). (Asian J Surg 2002;25(4):325–9)
MATERIALS AND METHODS
A total of 1,576 patients with thyroid disorders
underwent surgery in a general hospital unit between
1975 and 2000. Of these, 289 thyroid cancers were
analyzed for various prognostic indices. Of the 289
thyroid cancers analyzed, there were 215 differentiated
thyroid cancers, which were histologically classified
according to the World Health Organization (WHO)
classification.1 Thus, there were 132 papillary cancers
(63 in males and 69 in females) and 83 follicular cancers
(35 in males and 48 in females). The age at diagnosis
ranged from 12 to 75 years in the papillary cancer group,
with a mean of 37.5 years. In the follicular cancer group,
the age at diagnosis ranged from 4 to 75 years, with a
mean of 43.2 years (Figure 1).
The duration of symptoms at presentation was short in
both histologic types with a mean of 27.9 months among
patients with papillary cancer and 30.1 months among
those with follicular cancer. Overt cancers, i.e., tumours
Vol 25 • No 4 • October 2002326
SARDA AND OTHERS
with local spread and/or distant metastases, were present
in 63 papillary and 44 follicular cancer patients. Papillary
cancers in 48 patients and follicular cancers in 21 occurred
as clinically benign, solitary thyroid nodules. Eighteen
papillary and 17 follicular cancers presented as clinically
benign, euthyroid multinodular goitres. Four cancers
were encountered in patients who had undergone
operations for Grave’s disease; of these, three were
papillary and one was a follicular cancer.
Assessment of the extent of the disease was made by
clinical examination, radiological investigation,
radionuclide thyroid scan (performed routinely until
1988), radioimmunoassay of serum T4, T3 and TSH, and
fine-needle aspiration cytology (FNAC) of the primary
tumour and of the metastatic deposit (whenever possible).
Categorizing of the tumours was done according to
the TNM staging system (Figure 2).1 Thus, there were 60
patients with T0–2N0M0 papillary cancersof which
38 were < 40 years of age. There were 30 patients with
follicular cancers who presented at this early stage of the
disease, with 17 of them being < 40 years of age. There
were 34 patients with papillary and eight with follicular
cancers at stage T0–2N1–2M0, of which 24 patients with
papillary and three with follicular cancers were less than
40 years of age. Advanced stage (T3N3M1) cancer was
encountered among 38 patients with papillary and
45 with follicular cancers, of which 16 patients with
papillary and 14 with follicular cancer were less than
40 years of age.
Distant metastasis at presentation
were found in 17 papillary and 29
follicular cancers. Patients with
pulmonary metastasis were typically
asymptomatic at the time of detec-
tion of the lung of involvement.
Pulmonary involvement was found
in 11 papillary and 16 follicular
cancers. Skeletal metastases were
usually associated with bony pain
and/or pathological fracture and
occurred in five papillary and 26
follicular cancers. Surgery for the
primary tumour aimed at near-total
thyroidectomy while a hemi-
thyroidectomy was performed in
patients who did not have a definite
preoperative diagnosis and who
refused a completion thyroidectomy
at a second stage (Figure 3). The patients’ follow-up
ranged from 3 to 20 years (average, 12.6 years).
All patients were treated with suppressive doses of
thyroid hormone. In patients with complete remission
after the initial treatment of the tumour, clinical
examination, chest x-ray, and serum TSH and
thyroglobulin estimations were performed at 6, 12, 18
Figure 1. Age distribution.
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and 24 months and then annually. Whole body 131I scan
was performed 3 to 6 weeks after near-total thyroidectomy
to detect and treat any residual and/or metastatic disease,
followed 6 months later by a repeat whole body scan to
ensure total ablation of the disease. Recurrences were
defined as a separate appearance of the disease after
apparent previous control, regression or removal.
Progressive disease course without remission or a disease-
free interval was not classified as a recurrence. Thus,
contralateral lobe recurrence after hemithyroidectomy
occurred in 5/30 papillary and 3/13 follicular cancers.
Loco-regional recurrence, which was categorized
as a recurrence in the thyroid bed, residual thyroid
tissue, ipsilateral or contralateral lymph nodes or
lymph nodes of the upper mediastinum, or recurrence
in the other cervical structures, was seen in 32/99
patients with papillary and 13/65 patients with
follicular cancer undergoing near-total or subtotal
thyroidectomy. Mortality due to thyroid cancer occurred
in 26 patients with papillary and 28 patients with follicular
cancer.
Significance of the various parameters was calculated
using the chi-square test.
RESULTS
Although papillary cancer was the predominant
tumour in the patients studied and occurred in 46% of the
patients, follicular cancer in 29% and anaplastic and
squamous cell cancers in 13% also constituted large
percentages. Papillary cancers occurred at all ages, with
the majority seen in the third, fourth and fifth decades of
life (53.8% of patients < 40 years of age). Nonetheless, of
interest was the occurrence of follicular cancers in the
younger age groups (33.7% in patients < 40 years of age
and nearly 7% in patients < 19 years of age). Females
predominated, with 52.3% papillary and 57.8% follicular
cancers seen in females. The striking features, therefore,
regardless of histological type, were the occurrence of
tumours at an earlier age, the higher percentage of
follicular cancers in younger patients and the male to
female parity.
The commonest presentation of both histologic types
occurred as overt lesions (p > 0.05). There was a significant
difference in the size of the primary tumour at presentation.
There was no relationship to the age and sex of
the patient. Lymph node involvement was present in
52 papillary and 33 follicular cancers (p > 0. 1). Age and
sex of the patient did not affect nodal involvement.
Distant metastases were more common in patients with
follicular cancer (p < 0.001), were significantly higher
in the older age groups in both cancers and were
not affected by the gender of the patient Although there
was a significantly higher prevalence of skeletal metastases
in follicular cancers, there was no difference in the
metastases to the lungs (p > 0.1). If T0–2N0M0 is taken
as an early stage of the disease, 45.5% of papillary and
36.1% of follicular cancers were early cancers (p > 0.5).
Advanced T3N3M1 lesions occurred in 28.8% of papillary
and 54.2% of follicular cancers (p < 0.001). Although a
significantly higher number of papillary cancers occurred
as early lesions, there was no statistical difference in the
occurrence of follicular cancers among the various stages
of the disease. There was no significant difference in
the development of contralateral lobe recurrence
following hemithyroidectomy or the development of
loco-regional recurrence following subtotal or near-total
thyroidectomy between the papillary and follicular
cancers (p > 0. 5).
Mortality was high among patients with both histologic
types of cancer, but was significantly higher among
patients with follicular carcinoma (p < 0.05). Although
Figure 3. Surgery for differentiated thyroid cancer.
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mortality was significantly higher in patients ≥ 40 years
with papillary cancers (p < 0.05), age did not affect the
survival of patients with follicular cancer (Table). Gender
of the patient also did not reflect on the mortality in both
histological types of tumours. Mortality was significantly
higher in both histologic groups if the cancers at
presentation were advanced T3N3M1 lesions (p <
0.05); there was no difference in the mortality of early
T0–2N0M0 lesions in both histologic types.
Only two patients with early T0–2 size of the primary
tumour but N1–2 lymph node status died of the disease,
suggesting a better prognosis for patients with small
tumours metastasizing to the regional lymph nodes.
Death due to local recurrence of the tumour occurred in
50% of patients with papillary and 69% of patients with
follicular cancers; thus, 55% of patients with differentiated
thyroid cancers with loco-regional recurrence died of the
disease. Distant metastases at presentation signified a
poor prognosis, with 34% of patients with papillary and
48% of patients with follicular cancers succumbing to the
metastatic disease. Metastases to the lungs and the skeletal
system resulted in death in 31% and 27% of the patients,
respectively; all patients with metastasis to the brain,
vertebral column and liver died.
DISCUSSION
The patients studied were from a geographic area
endemic for goitres, where there was a relatively high
proportion of follicular cancers, generally implying
a worse prognosis. These patients were older, with
larger size primary tumours and fewer lymph node
metastases.3,4 Papillary cancers of the thyroid, on the
other hand, are recognized for a more favourable prognosis
and a greater incidence of lymph node involvement.
Nonetheless, these observations were not confirmed by
our study; we found no distinction between the two
histologic cancer types, and the disease had a short
duration of symptoms at presentation and displayed an
aggressive biological behaviour irrespective of the
histology. These findings are comparable to reports from
other areas endemic for goitres.2
Follicular cancers resulted in higher mortality than
did papillary carcinomas (p < 0.05), although mortality
was high in both groups. Besides the histology of the
tumour, extent of the disease and distant metastases at
presentation were considered in the univariate analysis
as factors affecting survival in our patients. These results
are similar to other reports stating that survival rates for
papillary and follicular carcinomas are similar among
patients of comparable age and disease stage.5,6
The age of the patient at the time of diagnosis is an
important consideration, as it influences outcome of the
disease.5,7–15 Follicular cancers are reported to occur in
older patients, with a median age at diagnosis typically in
the sixth decade of life,16 while the mean age of patients
with papillary cancers is reportly in the fifth decade.17
Our patients in both groups presented a decade earlier
than the ages reported in the literature. Except among
patients with papillary cancer, where the prognosis was
significantly better in patients less than 40 years of age,
age did not affect survival of patients with follicular
cancers.
Gender as a prognostic factor is currently being
debated,5,7–9,18 with some authors claiming the
importance of sex as one of the major determinants of
survival in differentiated thyroid cancers, with males
having a poorer prognosis.7–18 However, we could not
confirm this finding because survival among our patients
was not different between the two sexes, a finding that is
confirmed by other authors5,10–18
The extent of the disease also contributed to
the prognosis; advanced lesions conferred a worse
prognosis.3–7,11,16–18 A study of 157 differentiated thyroid
cancers included in the multicentric EORTC trial, places
tumour stage in first place as a prognostic factor.12 Our
findings of the extent of the disease as a predictor of death
are in agreement with these reports. Nonetheless, the
presence of lymphadenopathy did not have an
Table. Prognostic factors
                                   Histological type
Papillary, n (%) Follicular, n (%)
26 (132) 28 (83)
Age, years
    < 40 9 (71) 11 (28)
    ≥ 40 17 (61) 27 (61)
Sex
    Males 9 (63) 13 (35)
    Females 17 (69) 15 (48)
Stage
    T0–2N0M0 5 (60) 3 (30)
    T0–2N1–2M0 1 (34) 1 (8)
    T3N3M1 20 (38) 24 (45)
Distant metastases 9 (17) 13 (29)
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unfavourable effect on the prognosis of the disease in
our study. This was also noted by several other
authors.3,5,8–15,17,19 Finally, distant metastasis at
presentation was also an important prognostic variable.
Distant metastasis at presentation in 21% of our
patients occurred more frequently than in reports in the
literature5,13,14 Of our patients with distant meta-
stases, 47% died, confirming the findings of other
authors.3,4,14,17,19,20
Near total or total thyroidectomy is the surgical
treatment of choice for thyroid carcinoma.1,5 The extent
of surgery is a good indicator of the outcome. In the
present study, 32/99 (32.3%) papillary and 13/65 (20%)
follicular cancer patients who underwent near total
thyroidectomy developed loco-regional recurrence during
the 3 to 20-year follow-up period (p > 0.05). Death due
to local recurrence of the tumour occurred in 50% of
patients with papillary and 69% of patients with follicular
cancers; thus, 55% of patients with differentiated thyroid
cancers with loco-regional recurrence died of the disease.
In our study, the extent of the disease, especially the
presence of distant metastases at presentation, was the
most important determinant of survival, followed by
histology of the tumour and age, which was prognostically
significant only in cases of papillary cancer.
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